{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:25:43Z","timestamp":1790281543107,"version":"4.1.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00187","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T12:53:55Z","timestamp":1582289635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Immunotherapy in Malignant Pleural Mesothelioma"],"prefix":"10.3389","volume":"10","author":[{"given":"Cornedine J.","family":"de Gooijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S339","DOI":"10.1016\/j.jtho.2018.08.277","article-title":"OA08.03 phase II trial of pembrolizumab (NCT02399371) in previously-treated malignant mesothelioma (MM): final analysis","volume":"13","author":"Desai","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respirat Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabro","year":"2018","journal-title":"Lancet Respirat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respirat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 dream - a phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result","volume":"13","author":"Nowak","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"mdz394.001","DOI":"10.1093\/annonc\/mdz394.091","article-title":"LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Annal Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00262-014-1609-9","article-title":"CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic\/target therapy?","volume":"64","author":"Calabro","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"mdz266.013","DOI":"10.1093\/annonc\/mdz266","article-title":"1841OSecond\/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)","volume":"30","author":"Zalcman","year":"2019","journal-title":"Annal Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respirat Crit Care Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respirat Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.4049\/jimmunol.1102209","article-title":"Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients","volume":"187","author":"Alfaro","year":"2011","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thoracic Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the Anti\u2013PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J Thoracic Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3892\/ijo.2019.4883","article-title":"Role of evaluating tumorinfiltrating lymphocytes, programmed death1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma","volume":"55","author":"Losi","year":"2019","journal-title":"Int J Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"B27","first-page":"1007","article-title":"Lymphocytic infiltration of pleural mesothelioma and its significance for survival","volume":"61","author":"Leigh","year":"1982","journal-title":"Afr Med J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00262-016-1844-3","article-title":"CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor","volume":"65","author":"Roncella","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B33","year":"2018","journal-title":"Malignant Pleural Mesothelioma"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jtho.2018.08.2024","article-title":"Treat it or Leave it: immuno-Oncology in Mesothelioma Observed by the Eyes of Argus","volume":"13","author":"de Gooijer","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jtho.2018.05.003","article-title":"Revised modified RECIST criteria in malignant pleural mesothelioma (Version 1.1): a step forward in a long race","volume":"13","author":"Tsao","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1470-2045(13)70125-6","article-title":"Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study","volume":"14","author":"Buikhuisen","year":"2013","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(18)30193-1","article-title":"NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"19","author":"Gregorc","year":"2018","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural mesothelioma: COMMAND-a double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy- naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respirat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00187\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T12:53:56Z","timestamp":1582289636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00187\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":42,"alternative-id":["10.3389\/fonc.2020.00187"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00187","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"article-number":"187"}}